Journal
Bone Marrow Transplantation
Publication Date
6-9-2021
Volume
56
Issue
10
First Page
2477
Last Page
2488
Document Type
Open Access Publication
DOI
10.1038/s41409-021-01356-0
Rights and Permissions
Fløisand, Y., Schroeder, M.A., Chevallier, P. et al. A phase 2a randomized clinical trial of intravenous vedolizumab for the treatment of steroid-refractory intestinal acute graft-versus-host disease. Bone Marrow Transplant 56, 2477–2488 (2021). doi.org/10.1038/s41409-021-01356-0 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Recommended Citation
Fløisand, Yngvar; Schroeder, Mark A; Chevallier, Patrice; Selleslag, Dominik; Devine, Steven; Renteria, Anne S; Mohty, Mohamad; Yakoub-Agha, Ibrahim; Chen, Chunlin; Parfionovas, Andrejus; Quadri, Syed; Jansson, Johan; Akbari, Mona; and Chen, Yi-Bin, "A phase 2a randomized clinical trial of intravenous vedolizumab for the treatment of steroid-refractory intestinal acute graft-versus-host disease." Bone Marrow Transplantation. 56, 10. 2477 - 2488. (2021).
https://digitalcommons.wustl.edu/open_access_pubs/11680
Supplementary material
